tetradecanoylphorbol acetate and cc 3052

tetradecanoylphorbol acetate has been researched along with cc 3052 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barcellini, W; Dalgleish, AG; La Maestra, L; Lazzarin, A; Marriott, JB; Zaninoni, A	1

Other Studies

1 other study(ies) available for tetradecanoylphorbol acetate and cc 3052

Article	Year
The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro. Clinical and experimental immunology, 2000, Volume: 119, Issue:1 Topics: Anti-HIV Agents; Base Sequence; Cell Line; DNA Primers; Gene Expression; HIV Infections; HIV-1; Humans; In Vitro Techniques; Macrophages; T-Lymphocytes; Tetradecanoylphorbol Acetate; Thalidomide; Tumor Necrosis Factor-alpha; U937 Cells	2000

Article

Year

The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro.

Clinical and experimental immunology, 2000, Volume: 119, Issue:1

Topics: Anti-HIV Agents; Base Sequence; Cell Line; DNA Primers; Gene Expression; HIV Infections; HIV-1; Humans; In Vitro Techniques; Macrophages; T-Lymphocytes; Tetradecanoylphorbol Acetate; Thalidomide; Tumor Necrosis Factor-alpha; U937 Cells

2000